CompletedPhase 3NCT00452725
Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome
Studying Noonan syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sanofi
- Principal Investigator
- Marie SEBILLESanofi
- Intervention
- MAXOMAT ®, biosynthetic growth hormone(drug)
- Enrollment
- 36 enrolled
- Eligibility
- 3-15 years · All sexes
- Timeline
- 1997 – 2010
Study locations (1)
- Sanofi-Aventis, Paris, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00452725 on ClinicalTrials.govOther trials for Noonan syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07464821National Multicentre Study on Lipid Profile in Noonan Syndrome and Related Disorders: Trends by Age, Gender and GenotypeIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPHASE2NCT06555237MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathiesMedical University of Warsaw
- ENROLLING BY INVITATIONNCT05308927French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan SyndromeNovo Nordisk A/S
- RECRUITINGNCT05202210Constitution of a Biological Collection to Study the Pathophysiology in Noonan SyndromeUniversity Hospital, Toulouse